Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
436.95
-13.46 (-2.99%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
66
67
Next >
Which S&P500 stocks are moving on Tuesday?
↗
May 12, 2026
Via
Chartmill
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?
↗
May 11, 2026
The biotech's innovative platform could pay off.
Via
The Motley Fool
5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call
May 11, 2026
Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly launched therapies, with management hi...
Via
StockStory
Topics
Earnings
Is This Millionaire-Maker Biotech Stock a Buy Right Now?
↗
May 06, 2026
The market wasn't impressed by its latest quarterly update.
Via
The Motley Fool
Topics
Initial Public Offering
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Fits the Affordable Growth Profile With Strong Earnings and Reasonable Valuation
↗
May 05, 2026
Via
Chartmill
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 Estimates as New Drug Launches Drive Diversification
↗
May 04, 2026
Via
Chartmill
Vertex (VRTX) Q1 2026 Earnings Call Transcript
↗
May 04, 2026
Vertex (VRTX) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Vertex Pharmaceuticals Reports Mixed Q1 Results
↗
May 04, 2026
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports financial results for the first quarter after the market close on Monday.
Via
Benzinga
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 CY2026 Sales Expectations
May 04, 2026
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.8% year on year to $2.99 billion. ...
Via
StockStory
Vertex (VRTX) Q2 2025 Earnings Call Transcript
↗
May 04, 2026
Vertex (VRTX) Q2 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Stock with Promising Technical Setup
↗
April 29, 2026
Via
Chartmill
Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect
May 02, 2026
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what investors should know. Vertex Pharmace...
Via
StockStory
Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying?
↗
May 02, 2026
These longtime market beaters may not have peaked yet.
Via
The Motley Fool
Topics
World Trade
Set It and Forget It: 3 Monster Stocks Worth Holding Through Whatever Comes Next
↗
May 01, 2026
They may suffer the occasional knee-jerk setback. By and large, though, investors understand these companies are capable of standing up to almost any challenge.
Via
The Motley Fool
Topics
Credit Cards
Economy
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Presents a Compelling Growth and Technical Setup
↗
April 03, 2026
Via
Chartmill
Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering
↗
April 30, 2026
These companies are leaders in their fields.
Via
The Motley Fool
What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.
↗
April 30, 2026
The biotech's candidate may treat a great number of illnesses that have one thing in common.
Via
The Motley Fool
Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead?
↗
April 30, 2026
This particular player has seen its yield rise in recent years.
Via
The Motley Fool
3 Growth Stocks That Could Generate 10X Returns
↗
April 29, 2026
These stocks come with risk, but they also have some exciting long-term growth opportunities.
Via
The Motley Fool
Topics
Cannabis
Law Enforcement
3 of Wall Street’s Favorite Stocks Worth Your Attention
April 29, 2026
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Via
StockStory
3 Market-Beating Stocks to Consider Right Now
April 28, 2026
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...
Via
StockStory
Topics
Energy
3 Healthcare Stocks With the Most Durable Competitive Moats
↗
April 23, 2026
These companies offer a clear path to sustained earnings growth.
Via
The Motley Fool
Topics
Intellectual Property
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy?
↗
April 21, 2026
We'll know more about the company's medium-term prospects by the end of the year.
Via
The Motley Fool
2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term
↗
April 19, 2026
Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases.
Via
The Motley Fool
Is Vertex Pharmaceuticals' Empire in Trouble?
↗
April 16, 2026
It might not be too late to invest in this company.
Via
The Motley Fool
1 S&P 500 Stock on Our Watchlist and 2 Facing Challenges
April 16, 2026
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...
Via
StockStory
Topics
Stocks
Trump's Team Says Don't Worry About Rising Inflation. Here Are 3 Stocks to Buy If They're Wrong.
↗
April 14, 2026
Could the White House be overly optimistic about inflation? If so, you may want to own these stocks.
Via
The Motley Fool
Topics
Economy
Government
Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position?
↗
April 07, 2026
With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has attracted a big Investor.
Via
The Motley Fool
Topics
ETFs
1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds
April 02, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have ou...
Via
StockStory
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
March 31, 2026
In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500...
Via
MarketMinute
Topics
Economy
Intellectual Property
Stocks
< Previous
1
2
3
4
5
6
7
8
9
...
66
67
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today